"Dr. Robert Benezra, Ph.D. serves as Chairman of Scientific Advisory Board and Chief Scientific Officer at AngioGenex, Inc. Dr. Benezra has been a Member of Scientific Advisory Board of Provista Diagnostics, Inc. since June 28, 2012. Dr. Benezra serves as a Member of the Cell Biology Program at Memorial Sloan-Kettering Cancer Center. Dr. Benezra is Professor of Biology at Cornell Graduate School of Medical Sciences in New York City. Before joining Sloan-Kettering, Dr. Benezra worked at Fred Hutchinson Cancer Center in Seattle where he identified the Id proteins as dominant negative regulators of the helix-loop-helix protein family and has gone on to identify these proteins as key regulators of tumor growth, angiogenesis and metastasis. Dr. Benezra has been a Director of AngioGenex, Inc. since June 18, 2014. He has received fellowships and grant awards from the National Institutes of Health, the National Science Foundation and the American Cancer Society. Dr. Benezra received his doctorate in Biological Sciences at Columbia University in 1996."
My personal opinion is that AGGX will resume filing with the SEC at some point soon. It is my opinion also that they went dark in their early stages because they had deep-pocket friendly investors thus there has been no need to go the toxic financing route. Their patented anti cancer treatment is novel and has been very effective in animal testing. Clinical trials possible later this year
"Our intention to initiate clinical trials with our lead anti-cancer drug (AGX51-E2) is now supported by a commitment from The Trout Group, a highly respected investment firm in NYC. A contractual arrangement was completed in the latter part of 2014 and efforts are currently underway to present our technology and plans to potential investors. The Trout Group is taking an active part in these efforts and we expect that we will raise sufficient funds to launch preclinical efforts to achieve FDA approval for an IND that will allow us to initiate the first clinical trial in mid-2016."
Meaningful recent developments are:
Representation by The Trout Group http://www.troutgroup.com/clients/overview Memorial Sloan Kettering becoming a shareholder Robert Benezra PhD (AGGX lead researcher) becoming a board member and shareholder
AGX-51 patented by AGGX "Breast cancer metastasis remains one of the greatest clinical challenges in breast cancer. Thus it is critical to identify new therapeutic agents that are effective in inhibiting the development of metastasis. Dr. Benezra’s laboratory is studying a class of proteins called DNA binding/differentiation (Id) proteins (Id1 and Id3) as potential therapeutic targets to prevent metastasis. Id proteins have been shown to be overexpressed in primary and metastatic breast tumors and importantly, knocking out these proteins using genetic tools leads to a near complete inhibition of metastasis in experimental models. Dr. Benezra’s team identified an agent called AGX-51 that reduces the levels of Id1 and Id3 proteins leading to a decrease in lung metastases. When combined with the commonly used chemotherapy drug Taxol, AGX-51 further reduced lung metastases in a model of aggressive breast cancer. In the coming year, they will further investigate the antitumor activity of AGX-51 to better understand how it works to regulate Id1/Id3 proteins and will identify the gene expression changes associated with this action. These experiments are key to assessing the potential for novel anti-Id therapeutics in the management of metastatic breast cancer."
News 
Market Data 
Discover 
